Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by capebretongirlon May 27, 2021 9:51am
94 Views
Post# 33274779

RE:RE:Bash , pump investor . short.. other

RE:RE:Bash , pump investor . short.. otherThe interviews can't hurt, particularly with the likes of Lifton.  However, I agree that only sales and proof of acceptance vis a vis Aristotle and AVPT will count from here on in.  This is very much a "show me the money" stock due to over promising in the past and investors are simply not interested or impressed in hearing rosy but general forecasts.  The next test will be Q2 when we see what cancer revenue actually looks like.  In between we are all obviously hoping for a big signing on the cancer front as covid revenue clearly will not move the needle here.  I have to think as well that eyes are on Aristotle, particularly if we believe it to be what it is.

Mermer2328 wrote:
szls SP will only move lower on silence. James doing his piddly interviews means little to investors that have watched him eat his words over the last few years Show us the contracts, Arostotke tests performed among many other happenings.. that's what will move the SP.... nothing else By now they should know that


<< Previous
Bullboard Posts
Next >>